The US Food and Drug Administration has pushed the decision date on a second indication for AbbVie Inc.'s for Rinvoq out three months to late in the second quarter of 2021 to review additional safety data for the JAK1 inhibitor, the company said on 17 March. The delay and new scrutiny put future revenue potential at risk for a drug AbbVie is relying on to help offset Humira sales declines.
[Sidebar#SC143752]






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
